The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role

• Published in: Molecular cancer 2022-01, Vol.21 (1), p.30-30, Article 30
• Main Authors: Zuo, Jing, Zhang, Zhe, Li, Maomao, Yang, Yun, Zheng, Bohao, Wang, Ping, Huang, Canhua, Zhou, Shengtao
• Format: Article
• Language: English
• Subjects: Antioxidants; Apoptosis; Biomarkers; Cancer; Cancer diagnosis; Cancer therapies; Cancer therapy; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - metabolism; Chemoradiotherapy; Combined Modality Therapy; Development and progression; Disease Management; Disease Progression; Disease Susceptibility; Drug dosages; Drug therapy; Enzymes; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Health aspects; Homeostasis; Humans; Metabolism; Metastases; Metastasis; Neoplasm Metastasis; Neoplasms - diagnosis; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - metabolism; NF-κB protein; Non-coding RNA; Noncoding RNAs; Oxidative Stress; Prognosis; Proteins; Radiation; Reactive oxygen species; Reactive Oxygen Species - metabolism; Review; RNA, Untranslated - genetics; Signal transduction; Signal Transduction - drug effects; Therapeutic targets; Treatment Outcome; Tumorigenesis
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-021-01488-3

Oxidative stress (OS), characterized by the excessive accumulation of reactive oxygen species (ROS), is an emerging hallmark of cancer. Tumorigenesis and development driven by ROS require an aberrant redox homeostasis, that activates onco-signaling and avoids ROS-induced programmed death by orchestrating antioxidant systems. These processes are revealed to closely associate with noncoding RNAs (ncRNAs). On the basis of the available evidence, ncRNAs have been widely identified as multifarious modulators with the involvement of several key redox sensing pathways, such as NF-κB and Nrf2 signaling, therefore potentially becoming effective targets for cancer therapy. Furthermore, the vast majority of ncRNAs with property of easy detected in fluid samples (e.g., blood and urine) facilitate clinicians to monitor redox homeostasis, indicating a novel method for cancer diagnosis. Herein, focusing on carcinoma initiation, metastasis and chemoradiotherapy resistance, we aimed to discuss the ncRNAs-ROS network involved in cancer progression, and the potential clinical application as biomarkers and therapeutic targets.